Can a targeted drug combo outsmart an aggressive lymphoma?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed Non-GCB DLBCL (per 2016 WHO diagnostic criteria); 2. Whole-body PET/CT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion (per 2014 Lugano criteria); 3. Age 18-65 years, with expected survival \>3 months; 4. No prior anti-lymphoma treatment; 5. Signed written informed consent and ability to comply with protocol-required visits and procedures; 6. ECOG performance status 0-2; 7. Adequate organ and bone marrow function, defined as follows: * Hematology: Absolute neutrophil count (ANC) ≥1×10⁹/L, platelet count (PLT) ≥50×10⁹/L, hemoglobin (HGB) ≥8.0 g/dL; no granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 7 days prior to testing; * Hepatic function: Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; * Renal function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCR) ≥50 mL/min; * Cardiac function: NYHA Class III or below; left ventricular ejection fraction ≥50% by echocardiography; * Coagulation: International normalized ratio (INR) ≤1.5×ULN, activated partial thromboplastin time (APTT) ≤ULN +10s, and prothrombin time (PT) ≤ULN +3s; 8. Women of childbearing potential or male subjects with partners of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last dose. Exclusion Criteria: 1. Central nervous system involvement; 2. History of hypersensitivity to the study drug, drugs of the same class, or excipients; 3. Concurrent malignancy requiring treatment or intervention; 4. Major surgery within 4 weeks prior to treatment (excluding vascular access catheter placement or biopsy); 5. Presence of any life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's opinion, may affect patient safety or compliance with study procedures; 6. Uncontrolled cardiac symptoms or disease, including: i. NYHA Class II or higher heart failure; ii. Unstable angina; iii. Myocardial infarction within 1 year; iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; 7. Active bleeding; 8. Active, uncontrolled systemic bacterial, viral, fungal, or parasitic infection (excluding onychomycosis), or other clinically significant active disease process that, in the investigator's opinion, renders the patient unsuitable for clinical trial participation; 9. Known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome; 10. Exclusion of patients with active chronic hepatitis B or active hepatitis C. Patients with positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody at screening must undergo further HBV-DNA and HCV-RNA testing. Patients with stable hepatitis B (HBV-DNA \<2500 copies/mL or 500 IU/mL) on antiviral therapy and cured hepatitis C patients (below the limit of detection) may be enrolled; 11. Definitive history of neurological or psychiatric disorder, including epilepsy or dementia; 12. Pregnant or lactating women; 13. Receipt of other investigational agents within 1 month prior to first dose; 14. Any other factors that, in the investigator's opinion, may affect the evaluation of efficacy or safety in this study.